Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TP300 monotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma
2009-012097-12Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TP300 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Objective response rate (ORR). Started Jul 2009; status: completed.
02
Drugs
TP300
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-012097-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012097-12.